Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: A 12-week double-blind, placebo-controlled pilot study
Authors:
- Trino BaptistaTBTrino Baptista
- Euderruh UzcáteguiEUEuderruh Uzcátegui
- Nairy RangelNRNairy Rangel
- Yamily El FakihYFYamily El Fakih
- Tatiana GaleazziTGTatiana Galeazzi
- Serge BeaulieuSBSerge Beaulieu
- Enma Araujo de BaptistaEBEnma Araujo de Baptista
- 1 May 2008
- journal article
- research article
- Published by Elsevier in Psychiatry Research
- Vol. 159 (1-2) , 250-253
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trialSchizophrenia Research, 2007
- Sustainability of 8% weight loss, reduction of insulin resistance, and amelioration of atherogenic-metabolic risk factors over 4 years by metformin-diet in women with polycystic ovary syndromeMetabolism, 2006
- Weight loss in overweight patients maintained on atypical antipsychotic agentsInternational Journal of Obesity, 2006
- A Double-Blind, Placebo-Controlled Trial of Sibutramine for Olanzapine-Associated Weight GainAmerican Journal of Psychiatry, 2005
- Antipsychotic-Induced Venous ThromboembolismCNS Drugs, 2002